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Sulfurmustardisanalkylatingchemicalwarfareagentthatprimarilyaffectstheeyes,
skin, and airways. Sulfur mustard injuries can take several months to heal, necessitate
lengthyhospitalizations,andresultinsignificantcosmeticand/orfunctionaldeficits.His-
torically, blister aspiration and/or deroofing (epidermal removal), physical debridement,
irrigation,topicalantibiotics,andsteriledressingshavebeenthemaincoursesofactionin
themedicalmanagementofcutaneoussulfurmustardinjuries.Currenttreatmentstrategy
consists of symptomatic management and is designed to relieve symptoms, prevent in-
fections,andpromotehealing.Therearecurrentlynostandardizedoroptimizedmethods
of casualty management that prevent or minimize deficits and provide for speedy wound
healing. Several laboratories are actively searching for improved therapies for cutaneous
vesicant injury, with the aim of returning damaged skin to optimal appearance and nor-
mal function in the shortest time. Improved treatment will result in a better cosmetic and
functional outcome for the patient, and will enable the casualty to return to normal
activities sooner. This editorial gives brief overviews of sulfur mustard use, its toxi-
city, concepts for medical countermeasures, current treatments, and strategies for the
development of improved therapies.
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HISTORICAL PERSPECTIVE OF SULFUR MUSTARD USE
Sulfurmustard[bis(2-chloroethyl)sulfide;orHD]isapotentvesicating(blistering)chemical
warfare agent that was first used in the First World War by Germany against French troops
at Ypres, Belgium (1917). Since then, there has been evidence or allegations of HD use in
11 conflicts, including by Italy against Ethiopia in 1936, by Japan against China in 1937, by
Poland against Germany in 1939, by Egypt against Yemen from 1963 to 1967, and by Iraq
against Iran in the 1980s.1 In addition, its use was threatened in the early 1990s during the
Persian Gulf War. There are no peacetime industrial uses for HD. Aging HD stocks remain
hazardous to civilians. These munitions and stockpiles were discarded on land and into the
ocean during and after the Second World War. Periodically they surface during agricultural
or fishing activities, causing serious injury. Extensive production and stockpiling during
the Second World War, along with the known effects of HD on epithelial tissues, have
spurred agreements to ban its production and use. These agreements include the 1993
Chemical Weapons Convention (CWC)2 and agent destruction programs. Nonetheless, this
chemical warfare agent remains a threat owing to its popularity in some countries that are
not signatories to the CWC and to accidental exposures. Dispersed as a vapor, aerosol, or
in liquid droplets, HD remains a threat to war fighters and civilians worldwide.
As a class, vesicants include sulfur mustard, the nitrogen mustards (HN1, the
chemotherapeutic agent HN2 or “Mustargen,” and HN3), arsenicals such as Lewisite, and
halogenatedoximessuchasphosgeneoxime.Aplethoraofinformationonvesicantsisavail-




The known molecular mechanisms of action, chemistry, toxicodynamics, and genotoxic-
ity of HD as well as the pathogenesis and histopathology of HD injuries have been widely
described.1,3–16 Becauseitsactionspartlyresemblethoseofionizingradiation,HDissome-
times considered a radiomimetic compound. Papirmeister et al1 wrote an extensive review
of HD research, offered several theories of its cytotoxicity, and summarized what is known
of its absorption, distribution, biotransformation, and excretion. Somani et al3 have also
provided an excellent overview of the toxicodynamics of HD.
Current research is not only investigating various aspects of Papirmeister’s theories,
but also actively pursuing the development and use of topical skin protectants, decontam-
inating agents, prophylactic and therapeutic countermeasures, and improved therapies for
established lesions. Most of the research to date has focused on mitigating cutaneous
injury. Larger knowledge gaps exist for injury to the eyes and the respiratory system, and
for systemic effects.
General clinical manifestations
Sulfur mustard is a bifunctional alkylating agent that causes extensive incapacitating in-
juries to the skin, respiratory tract, and eyes. It reacts with a large variety of molecules
of biologic interest, ranging from compounds of low molecular weight to macromolecules
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such as DNA, RNA, and proteins.1 Similar to other alkylating agents, it can cross-link com-
plementary strands of DNA and thereby inhibit cell division. Although injury occurs very
rapidly after tissue contact with HD, clinical signs of injury are delayed from 2 to 24 hours
following exposure, with the length of the delay being inversely proportional to exposure
level and other factors.16 Because of this delay and lack of pain on contact, exposures can
go unrecognized, and exposed persons may often fail to take immediate decontamination
and protective measures, resulting in extensive exposure and severe injury.
Characteristic lesions are a function of dose and time after exposure.1 At low toxic
doses, skin lesions are characterized by an initial asymptomatic period of highly variable
duration followed by localized pruritic erythema.1,15 Higher doses initially produce small
vesicles within or on the periphery of the erythematous areas that may later merge to form
large, pendulous blisters.15 Vesication may take several days to complete. Very high doses
produce coagulation necrosis, which is often characterized as “doughnut burns” owing
to the appearance of a central necrotic region of skin surrounded by a circular periph-
ery of less damaged tissue.15 Secondary bacterial infections of this type of wound pose a
serious threat. In the eyes, low vapor exposures are characterized by reddening. As the con-
centration increases, conjunctivitis becomes progressively more severe, with photophobia,
blepharospasm, pain, and corneal damage seen at higher doses.1,15 Liquid or very large
vapor exposure to the eyes results in severe corneal damage, with potential for blindness.15
Inhalation of HD vapor induces changes in laryngeal and tracheobronchial mucosa, with
mild to severe inflammation.1,15 Depending on the degree of exposure, symptoms can
range from a mild irritation of the upper respiratory tract to severe bronchiolar damage
leading to epithelial necrosis, hemorrhage, inflammatory exudate, and pseudomembrane
formation in the tracheobronchial tree.1,15 While rare, massive pulmonary exposure can
result in hemorrhagic pulmonary edema. In the First World War, respiratory injury from
vapor exposures resulted in death due to pneumonia secondary to chemical pneumonitis.15
More profound respiratory injury from aerosol exposures, as in the Iran-Iraq war of the late
1980s, have resulted in 2 waves of death.17 The first wave occurred within 3 days of the
attack from respiratory failure due to extreme injury to respiratory epithelium and alveoli.
The second wave of deaths occurred between 1 and 3 weeks postexposure and resulted
from secondary bronchopneumonia and sepsis secondary to marrow failure. High doses
may produce a systemic toxicity that includes destruction of bone marrow precursor cells.
Leukopenia typically begins 3 to 5 days after exposure15 and may progress to pancytopenia.
Very high doses may induce destruction of lymphoid organs and the mucosa of the small
intestine and produce effects in the central nervous system, including apathy, depression,
hyperexcitability, abnormal muscular movements, and convulsions.1,15
Sulfur mustard has been shown to be carcinogenic and mutagenic in animal studies,
andepidemiologicalstudiesoffactoryworkersinvolvedinHDproductionwhowerechroni-
callyexposedtolowdosesofHDhaveimplicateditinhumancancers(primarilyrespiratory
carcinomas).1,15,16 Skin cancers have been experimentally generated in rats and mice ex-
posed to HD and can potentially arise in HD-induced scar tissue in humans.15,16 There is
no evidence that HD is a cause for adverse reproductive events, although epidemiological
study of heavily affected civilian populations may alter current understanding.
Persistent problems of soldiers and factory workers exposed during the First World
War include chronic bronchitis, asthma, laryngitis, recurrent pneumonia, and long-term
keratitis.16 Recent clinical reports of follow-up examinations of survivors of the 1987 Iraqi
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attack on Sardasht, including those who were children at the time, indicate chronic derma-
tological, ophthalmic, and respiratory problems.17,18 Pulmonary dysfunction was the most
common problem reported. It was noted that chronic effects tended to be significantly more
pronounced in adults, possibly because mechanisms of cellular repair are more dynamic in
children.18
Hypotheses of cytotoxicity
There are several hypotheses of HD cytotoxicity: (1) the poly(ADP-ribose) polymerase
hypothesis, (2) the thiol-Ca2+ hypothesis, and (3) the lipid peroxidation hypothesis.1 None
ofthesehypotheseshasbeenfullyaccepted,andthemechanismsproposedbythesetheories
may be active at the same time. At present, the exact mechanism of action of HD is not
known.
The first hypothesis, originally proposed by Papirmeister,1 has been coined the
poly(ADP-ribose)polymerase(PADPRP)hypothesis.Sulfurmustardinjuryisinitiatedbya
rapid alkylation of DNA. Alkylated DNA purines undergo spontaneous enzymatic depuri-
nation, resulting in numerous apurinic sites that are subsequently cleaved via apurinic
endonucleases to form DNA breaks. Accumulation of these breaks activates the chromoso-
mal enzyme PADPRP, which uses NAD+ as a substrate to ADP-ribosylate several nuclear
proteins,resultinginadepletionofcellularNAD+.N AD + depletionappearstobetheresult
of an accelerated rate of use, as opposed to interference with its synthesis. This depletion
results in the inhibition of glycolysis and subsequent stimulation of the NADP+-dependent
hexose monophosphate shunt (HMS) owing to accumulation of glucose-6-phosphate. Ac-
tivation of the HMS results in induction and secretion of proteases, which in turn lead to
the typical pathology changes noted above. Results from in vivo studies using a human skin
graft model and in vitro work using human lymphocytes, human keratinocytes, and human
skin organ cultures suggest that NAD+ levels that decrease below a critical value become
irreversible and injury-producing. Nuclear pathology appears to precede cytoplasmic dam-
age. This nuclear damage is characterized by loss of euchromatin and condensation and
margination of heterochromatin.1 Severe damage to the nuclear envelope, such as blebbing
and breakage, has been demonstrated by electron microscopy, along with the formation
of perinuclear vacuoles. The extent of nuclear damage has been shown to be dose- and
time-related.1
EvidencethatmaycontradictthePADPRPhypothesisincludesthefactsthat(1)NAD+
depletion does not occur in rat keratinocytes until the concentration of HD is sufficient to
inhibit DNA repair19; (2) DNA repair in human keratinocytes may be accomplished within
90 minutes of exposure,20 whereas significant NAD+ depletion is not observed until 1 to
3 hours postexposure; and (3) elevation or maintenance of NAD+ in human keratinocytes
does not confer protection.21
The second hypothesis of HD cytotoxicity, the thiol-Ca2+ theory, is based on a mech-
anism originally proposed by Orrenius and Nicotera in their studies of rat hepatocytes.22
The initiating event here is a reduction in cellular protein thiol levels, leading to toxic
increases in free cytosolic Ca2+ levels. The thiol levels are depleted as a result of direct
reactions of glutathione (GSH) and protein sulfhydryls with oxidants or other electrophilic
xenobiotics. Glutathione is an intracellular scavenger of HD, which may be the cause
of GSH depletion. Depletion of GSH occurs following reaction with electrophiles, thus
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exposing protein sulfhydryls to damage by the xenobiotic or by endogenously produced
toxic oxygen species that arise as by-products of oxidative metabolism. Alternatively, HD
may also react directly with protein thiols to cause the inactivation of enzymes. One group
of enzymes affected by modification of its sulfhydryl groups is Ca2+ translocases, result-
ing in alteration of intracellular Ca2+ homeostasis. This leads to an increase in cytoso-
lic free Ca2+,w hich in turn leads to activation of Ca2+-dependent catabolic processes,
including stimulation of proteases, endonucleases, and phospholipases. Protease activity
leads to protein degradation and ultimate perturbation of the cytoskeleton. Changes in
the cytoskeleton may also arise from direct alkylation by HD on microfilamentous pro-
teins, although this does not appear to play a critical role. Endonuclease activity leads to
DNA breaks, leading to chromatin condensation and energy loss in the cell. Activation
of phospholipases leads to phospholipid hydrolysis, with subsequent alterations in mem-
brane fluidity and loss of membrane protein function and integrity. The cytoskeletal, nu-
clear, and membrane changes all lead to cell death.1 It is not known whether vesicat-
ing doses of HD deplete GSH sufficiently to produce these cytotoxic effects. Slow GSH
depletion may be less toxic because it allows time for cell adaptation. The lengthy la-
tent period prior to clinical manifestation of HD lesions is inconsistent with the more
rapid injury expected from an alkylation-induced GSH depletion, suggesting that dam-
age to a cellular target other than GSH is responsible for initiating the cytotoxicity
and that any involvement of the thiol-Ca2+ cytotoxic pathway results from this initial
damage.
The third hypothesis involves lipid peroxidation distinct from the thiol-Ca2+ hypothe-
sis, where the principal toxic consequence of GSH depletion is the formation of toxic lipid
peroxides. Cell death is thus proposed to be due to an accumulation of endogenous oxidants
(eg, H2O2 accumulation resulting in hydroxyl and perferryl ion formation), leading to lipid
peroxidation and irreversible membrane damage.1
MorerecenttheoriestoaccountforthemechanismofHDtoxicityincludeamelanocyte
free-radical hypothesis23 and one in which HD requires metabolic activation.24 Owing to
the multiple molecular targets of HD, multiple pathways to cell death may be initiated.
These multiple pathways may have some common steps; hence, all of the above hypotheses
may play a role in the cytotoxicity of sulfur mustard. Papirmeister25 also explained how
HDcouldinduceapoptosis(programmedcelldeath)andpostulatedhowitmightcontribute
to or modify the pathogenesis of HD injury. Kan et al26 postulated that HD-induced cell
death involves early apoptosis (6–12 hours postexposure) and late necrosis (24 hours),
whichtemporallyoverlaptoproduceasinglecell-deathpathwayalonganapoptotic-necrotic
continuum. Several lines of research are underway to further elucidate the role of apoptosis
in HD toxicity.
Pathogenesis of blisters
The cytotoxic effects of HD on skin have been widely described for a number of
species.1,4,6,10,27–35 The primary cutaneous cell population targeted by HD is the basal
cell of the epidermis. Blisters (humans) and microblisters (animal models) occur on separa-
tion of the epidermis from the dermis at the dermal-epidermal junction. This separation is
dependent on the loss of integrity of basal cells and anchoring filaments.4 In animal model
studies, the development of an apparent initial nuclear pathologic condition of basal cells
5JOURNAL OF BURNS AND WOUNDS VOLUME 4
of the stratum germinativum was followed by progressive cytoplasmic changes, leading to
the eventual death of affected basal cells. Petrali et al4 described degenerative subcellular
effects of HD on the skin of hairless guinea pigs 24 hours after exposure. Degeneration
was also observed in human lymphocytes and keratinocytes in vitro by Petrali et al,4 in a
variety of animal models by Papirmeister et al,1,34 and in rabbits and guinea pigs by Vogt
et al.6 While degenerative changes are noted in the upper layers of the epidermis as well
as in epidermal cells of hair follicles, changes are most prevalent among basal cells, with
the earliest and most severe degeneration seen in cells located above the dermal papillae.1
Microblisters are observed to arise from focal areas of epidermal-dermal separation in ar-
eas of widespread basal cell pyknosis, 24 to 48 hours after HD exposure, as seen by light
microscopy. Progressive changes reported in basal epithelial cells include formation of
perinuclear or paranuclear vacuoles, a decrease in nuclear staining intensity, cytoplasmic
swelling, relocation of chromatin to the periphery of the nucleus, loss of chromatin, and
pyknosis.33 These changes are followed or accompanied by necrosis, vacuolization, or hy-
dropic degeneration of the cytoplasm.33 While the extent of nuclear damage is dose- and
time-related, it does not take place simultaneously in all basal cells examined, probably
reflecting differing repair efficiencies of cells in various phases of the cell cycle.1 Nuclear
pyknosis has also been described following HD exposure in human skin equivalent.36,37
It was also described in isolated perfused porcine skin flaps exposed to the HD simulant
2-chloroethylmethylsulfide,amonofunctionalanalogofHD.38 Thetimeofonsetofnuclear
or cytoplasmic changes is species-specific. In general, pyknotic nuclei begin to appear in
the basal cell layer 3 to 6 hours after HD exposure. By 12 hours, focal areas of pyknosis are
seen and become widespread by 24 hours, with the nuclei of many suprabasal keratinocytes
becoming involved.
The pathogenesis of microblisters is not fully understood. Petrali et al5,39 found indi-
cations that proteins of extracellular matrices of the basement membrane zone (BMZ) are
affected during the development of HD-induced skin pathology in hairless guinea pigs and
postulatedthattheymaycontributetotheformationofmicroblisters.Immunohistochemical
staining for bullous pemphigoid antigen, a noncollagenous protein shared between basal
cell hemidesmosomes and the lamina lucida, revealed a diminishing of bullous pemphigoid
antigen reactivity at early times and subsequent loss of antigenicity at later time periods
after an 8-minute HD vapor exposure (tissues were harvested at selected postexposure time
periods up to 24 hours). Laminin, the major glycoprotein of the lamina lucida, showed
scanty immunolocalization at the later time periods, conforming to the structurally altered
lamina lucida at microblister lesion sites. The reactivity of Type IV collagen, a ubiquitous
protein assigned to the lamina densa of basement membranes, was unaltered to specific an-
tisera throughout prevesication and vesication time periods. The influence of these altered
macromolecules on repair mechanisms following HD toxicity is not known. Other proteins
of the BMZ yet to be investigated or discovered likely play a role in the pathogenesis of
HD-induced microblisters.
Chemical properties
A summary of the chemical, physical, environmental, and biological properties of HD and
othervesicatingagents(Lewisite,phosgeneoxime)canbefoundinTheTextbookofMilitary
Medicine.15 Sulfur mustard is a pale yellow to dark brown oily liquid, with an odor of garlic
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or mustard. It has low solubility in water and is highly lipophilic, so it readily partitions
into the skin. Rates of 150 µgc m –2 min–1 through human skin in vivo40 and 157 µg
cm–2 min–1 through heat-separated human skin in vitro41 have been reported. Penetration
is enhanced by moisture and heat, and in thin skin. The LD50 of liquid HD is about 100 mg
kg–1. This is enough fluid (5–6 mL) to cover about 25% total body surface area (TBSA) in
an adult.15 A 10-µg droplet is enough to cause vesication. The threshold for vapor/aerosol
to induce damage is 200 to 2,000 mg min m–3 (concentration time, Ct), dependent on the
anatomical location, environmental conditions (temperature and humidity), sweating, and
otherfactors.15 Vaporinjurygenerallyinducessuperficialorpartial-thicknessdermalinjury.
Liquid HD can produce full-thickness injury. Because of its high freezing point (14◦C), HD
isverypersistentincoldandtemperateclimates.Itspersistenceislowerinwarmerclimates,
where the agent vaporizes more easily.
Clinical dermal effects
Clinically,erythemaisthefirstsymptomnoted,typicallywithadelayedonsetof4to8hours.
Pruritis, burning, or stinging may accompany the erythema.15 Slight edema may also be
present.Iftheexposurewassmall,theerythemawillnotprogresstovesication.Ifthelesion
progresses, very small vesicles will develop within or on the periphery of the erythematous
areas beginning at about 2 to 18 hours postexposure.15 These vesicles can later coalesce
to form large blisters/bullae. Vesication may take several days to complete. Additional
(new) blisters may arise a week later. Extremely high doses may induce a central zone of
coagulation necrosis, with blisters forming along the periphery. Sulfur mustard blisters are
subepidermal.Smalleronesarequitedurablebutlargebullaearevulnerabletofriction.The
blisterfluidisinitiallythinandclear,orslightlystraw-colored,andlaterturnsyellowishand
tends to coagulate. It does not contain unreacted agent and is not a vesicant itself, unlike the
fluid in Lewisite-induced blisters.15 High environmental temperatures, hydrated skin, thin
or delicate skin, or skin occluded by clothing will generally exhibit more severe lesions and
shorter times to onset of symptoms than cooler, less hydrated, thicker, or unoccluded skin
under similar levels of exposure. The face, neck, antecubital fossae, axillae, perineum, and
externalgenitaliatendtobeverysensitiveareas.DifferencesinindividualsensitivitytoHD
have been noted. Skin color has not been shown to affect HD penetration rates.42 Transient
hyperpigmentation was reported in casualties of the 1980s Iran-Iraq War, primarily due to
accumulation of melanin derived from dead melanocytes at the base of an epidermis about
to desquamate, and from opacification and darkening of nonviable epidermal cells.15,43,44
Following desquamation, the skin may appear hypopigmented. It is our opinion that long-
term hyperpigmentation results from stimulation of melanocytes and hypopigmentation
from melanocyte destruction. These pigmentary changes usually reverse in 6 to 12 months,
but can be permanent.
Healing time of these dermal injuries depends on severity, with erythema alone tak-
ing several days to subside and severe lesions taking weeks to months depending on the
anatomical location, depth of injury, and size. Lesions can be painful and secondary bac-
terial infection is a common problem (only in humans). While full reepithelialization has
sometimes been considered as an endpoint for healing, barrier function must return for the
lesion to be considered completely healed. Preliminary data from our laboratory indicate
that barrier function, as indicated by transepidermal water loss (TEWL) measurements, is
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severely disrupted in ventral abdominal pig skin by 3 to 7 days after 30 to 120 minutes of
exposure to liquid HD. While full reepithelialization of these deep dermal/full-thickness
injuries appears grossly to occur 35 to 56 days after exposure, TEWL values do not return
to baseline until 63 to 70 days postexposure (J. S. Graham et al, unpublished data, 1998).
The delay in barrier disruption following agent exposure can be explained by the in situ ex-
istence of an intact stratum corneum for the first few days following exposure. The stratum
corneum remains intact for 2 to 3 days, after which barrier function becomes compromised
(ie, TEWL rates greatly increase) owing to loss of sloughing epidermis or deroofing of a
blister. Following wound closure (eg, complete coverage of the damaged area by migrating
keratinocytes), additional time is needed to form a fully stratified epidermis with a well-
formed stratum corneum. Poor barrier function is generally attributed to an imbalance in
water content, lack of proper organization, and/or adhesion of the corneocytes that make
up the stratum corneum.
Long-term cutaneous effects
Residual health effects of significant HD exposure are usually respiratory, ocular, or cu-
taneous. The permanent consequences of cutaneous injury can include hypopigmentation,
hyperpigmentation, fragile skin that is easily damaged by trauma, and hypertrophic scar-
ring. Skin hypersensitivity and chronic ulceration problems have also been reported.16
Hypertrophic scarring is a result of uncontrolled fibroblastic activity and overgrowth of
connective tissue during wound repair.16 Excessive wound contraction has been noted in
aw eanling pig model following deep dermal/full-thickness HD injury45 and observed in
human casualties.44 Excessive scarring and/or wound contraction over joints is disfiguring
and impedes dexterity and locomotion. If initial treatment is not sufficiently aggressive
and excessive wound contraction and scar tissue formation occur, surgical release may be
indicated. As it is generally accepted that skin cancers can arise in scar tissue, HD-induced
scars can be considered to have a carcinogenic potential. It has previously been noted that
cutaneous cancers resulting from acute HD exposures usually localize in scars.16 While cu-
taneous malignancies have been reported, they appear to be an uncommon consequence of
HD exposure if indeed they were due to HD exposure alone.46 Theories on the mechanism
for malignant expression abound.
CONCEPTS FOR MEDICAL COUNTERMEASURES TO SULFUR MUSTARD
Concepts for medical countermeasures to vesicant agents have been developed and ac-
tive research programs are underway in a number of North Atlantic Treaty Organization
(NATO) countries. Institutes actively involved in this research area include the US Army
Medical Research Institute of Chemical Defense, located at Aberdeen Proving Ground,
Md, the Biomedical Sciences Department of the Defence Science and Technology Labora-
tory, Porton Down, Salisbury, Wiltshire, UK, and the Defence Research and Development
Canada–SuffieldMedicineHat,Alberta.Developedresearchconceptsincludeelimination
of body contact, improved decontamination, pharmacological intervention, and chemical
casualty management.
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Elimination of contact
The initial step in protecting a person from the deleterious effects of HD is to eliminate
contact with the agent. Respirators/protective masks can be donned to eliminate respiratory
and ocular exposures,47 specialized protective clothing (including suit, gloves, and foot
protection) can be donned to prevent the agent from reaching the skin,47 and topical skin
protectants48–62 can be used to protect areas of the skin vulnerable to the agent (eg, wrist,
ankle, waist, and neck junctions in protective clothing).
Decontamination
Skin injury from HD can be completely avoided through rapid physical removal, ideally
within minutes. Removal in less than 2 minutes completely prevents damage, but even later
removal lessens injury.15 Physical removal without agent neutralization (eg, wiping with
clothorgauze,scrapingwithtonguedepressor)canremovebulkagentfromtheskinandhelp
reducetheseverityofanyresultantlesion.Copiousquantitiesofwaterwithsoapappeartobe
quite effective in physically removing liquid HD from the skin surface.63 Decontamination
can also be performed by physical adsorption with or without chemical inactivation. There
are a number of decontaminating agents available to remove the agent that are based on
reactive powders (eg, Ambergard XE-555 Resin [Rohm and Haas Company, Philadelphia,
Pa]63), neutralizing solutions (eg, 0.5% hypochlorite63), reactive skin lotions (eg, Reactive
SkinDecontaminationLotion[RSDL,O’DellEngineeringLtd/E-Z-EM,Inc,LakeSuccess,
NY]64),orabsorbentpowders(eg,fuller’searth).Equallyeffective,however,arecommonly
available household products such as baking flour followed by wet wipes.65 Solvents such
as kerosene and surgical spirit may also be effective for removing HD from skin.66
Wound healing studies using weanling swine have demonstrated that following expo-
sure to undiluted liquid HD for 120 minutes, there is a significant period of off-gassing
of unbound agent, as measured by a MINICAMS air monitor (OI Analytical, College Sta-
tion, Tex; J. S. Graham et al, unpublished data, 2001). Quantification and localization of
the HD depot responsible for this lengthy off-gassing in this animal model has not been
performed. The existence of a dermal reservoir of HD in humans was first suggested in
World War 1 by Smith et al,66 who demonstrated that HD injuries could be prevented by
washing contaminated skin with an appropriate solvent up to 45 minutes postexposure.
Furthermore, Smith et al demonstrated that the skin reservoir of HD could be transferred
to a second individual, even after the exposed surface had been decontaminated. How-
ever, studies conducted during the Second World War reported the opposite effect in that
HD was rapidly “fixed” by skin constituents such as proteins.40 Contemporary in vitro
studies have confirmed the original finding of Smith et al that a substantial reservoir of
HD is formed in human skin that can account for up to 35% of the applied dose after
24 hours.41 This reservoir has been localized to the stratum corneum and upper epidermis.
ThissubstantiatesworkconductedbyCullumbine67 whichdemonstratedthattheprocessof
vesication could be blocked by the timely application of “peeling” (keratinlytic) agents up
to 14 hours postexposure. The existence of an HD depot in human skin for a period of time
following exposure has implications for the safety of medical emergency personnel treating
HD casualties; for example, use of protective apparel may be warranted. Prior to medical
treatment or casualty transport in enclosed vehicles, thoroughness of cleansing should be
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ensuredthroughmultiplewashingsand/oruseofadetector.Theexistenceofanagentdepot
could also influence the design of decontaminating agents. Any decontaminating agent that
is capable of pulling the targeted agent out of the skin as well as neutralizing it on the
surface of the skin has the potential to decrease HD-induced pathology, even beyond the
2-min efficacy window15 of conventional decontamination procedures.
Understanding the kinetics of HD skin absorption, and the amount and persistence of
unbound HD in putative agent reservoirs, will aid in choosing the most appropriate decon-
taminating agent and in determining its application doctrine and its window of effective
use. The best agent will be the one that not only decontaminates HD sitting on the surface
of the skin, but also is capable of fully penetrating the stratum corneum and neutralizing
any unbound agent reservoir located there, unlike previous reactive therapies.68 Research
is underway to develop an in vitro model for efficacy testing of advanced decontaminating
agents capable of pulling HD out of the skin reservoir and neutralizing HD on the surface
of the skin, to identify the most appropriate animal model for extrapolation of animal data
to humans, and to conduct in vivo efficacy tests of candidate decontamination systems.
Pharmacological intervention
Because HD is not painful on contact, the exposed person may not be aware of the expo-
sureuntilsymptomsbegintoappearafterthelatentperiod.Pharmacologicalapproachesare
beingstudiedfortheirefficacyinminimizingorpreventingthatdamage.69–71 Themostsuc-
cessful strategies to date have included the use of anti-inflammatories, protease inhibitors,
intracellular scavengers, cell cycle inhibitors, PADPRP inhibitors, and calcium modulators,
(Dr William J. Smith, PhD, US Army Medical Research Institute of Chemical Defense,
Aberdeen Proving Ground, Md, oral communication, 2004). It is interesting to note that
pretreatments (eg, antioxidants) that reside in the extracellular matrix are generally more
effective than those designed for intracellular protection against HD (Defence Science and
TechnologyLaboratory,PortonDown,unpublisheddata,2004).Thismayimplythatthecy-
totoxic effects of HD are mediated via interaction with cell surface components rather than
intracellulartargets.Thus,furtherinvestigationsoftheinteractionofcell-surfacemolecules
with HD may provide a new insight into the mechanisms of HD toxicity.
Chemical casualty management
When HD comes in contact with the skin, decontamination is not performed in a timely
fashion, and pharmacological intervention is absent or not adequately effective, a chemi-
cal casualty will be produced that requires medical attention. Casualty management now
comes into play, discussed in depth in the next section. Educational material and training
courses are available through the Chemical Casualty Care Division of the US Army Med-
ical Research Institute of Chemical Defense, Aberdeen Proving Ground, Md (on the Web
at https://ccc.apgea.army.mil/default.htm, by phone at 410-436-2230/3393, or by e-mail at
ccc@apg.amedd.army.mil).
CURRENT TREATMENTS FOR CUTANEOUS SULFUR MUSTARD INJURIES
There are currently no standardized or optimized methods of casualty management and no
drugs available to prevent the effects of HD on skin and mucous membranes. Historically,
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blister aspiration and/or deroofing (epidermal removal), physical debridement, irrigation,
topical antibiotics, and sterile dressings have been the main courses of action in the medical
management of cutaneous HD injuries.12,14,15,72,73 Current treatment strategy consists of
symptomatic management and is designed to relieve symptoms, prevent infections, and
promote healing. The general recommendations listed below are fully described in the Text-
book of Military Medicine,15 the Field Management of Chemical Casualties Handbook,74
the Medical Management of Chemical Casualties Handbook,75 and the NATO Handbook
on the Medical Aspects of NBC Defensive Operations.76
The decision to evacuate and hospitalize an HD casualty is based on the extent
and severity of the skin lesions, in consideration with other injuries that may be present
(eg, respiratory, ocular). For patients experiencing only cutaneous HD injuries, erythema
covering more than 5% TBSA in noncritical areas requires hospitalization. Erythema cov-
ering less than 5% TBSA may require hospitalization, depending on the site of the injury
(eg, face, inguinal area) and level of impairment (eg, limitation of limb movement due to
pain, edema). Total body surface area can be determined using Wallace’s Rule of Nines
and the Lund and Browder chart for estimating burn severity.77,78 Multiple or large areas of
vesication will also require hospitalization. Since blister formation may initially be slight,
the patient should be watched for a progression in the size and number of blisters. Topical
antibacterial creams such as silver sulfadiazine or 10% mafenide acetate can be prescribed
to patients not requiring close medical monitoring, with instructions to apply a thin layer
to the affected area 4 times a day. Following application of the cream, the area should be
covered with a petrolatum gauze bandage.
Not all burn injuries require specialized care in a burn center. The American Burn
Association has well-defined criteria for patient transfer to such a center,78 which should
serve as additional guidance in deciding where to hospitalize an HD casualty.
Before commencement of any treatment, clothing should be carefully removed and
treated as potentially contaminated, and the patient thoroughly decontaminated. For a gen-
eral overview of decontamination procedures, the reader is directed to Hurst’s chapter on
decontamination in the Textbook of Military Medicine.63
Direct comparisons in the literature between HD and thermal burns are scarce.
Papirmeister noted that disintegration of the basal cell layer caused by thermal burns has
been shown to produce an intraepidermal blister that contains fragments of the basal cell
layer attached to the basal lamina, unlike the almost totally denuded basement membrane
in HD lesions.1 An argument against the adage “a burn is a burn” is that HD initially targets
a specific cell type (epithelial basal cells), unlike a thermal burn that begins damage at the
stratum corneum and then works its way downward. Since stratum corneum is the structure
largely responsible for barrier function, water loss rates are very high immediately after a
thermal burn (140–180 g m–2 h–1 in humans).79 The stratum corneum remains intact for
2t o3days after a cutaneous HD injury, after which barrier function becomes compromised
by loss of sloughing epidermis or deroofing of the blister. The systemic fluid derangement
seen in cutaneous HD injury is less than that seen with thermal burns. Fluids and elec-
trolytes should be closely monitored, since fluids may be lost to edematous areas, with
resultant dehydration. Medical personnel are cautioned not to overhydrate the patient; hy-
pervolemiaandpulmonaryedemacanbeiatrogenicallyinducedinHDcasualties.15,44 Fluid
requirements in Iranian casualties during the Iran-Iraq war appeared to have been relatively
independent of TBSA.44 The recommended infusion rates and formulas used to calculate
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total volume requirements for thermal burn patients, based on body weight and TBSA,80
should not be routinely applied in HD casualty management. The exact fluid replacement
requirements for cutaneous HD injuries should be based on patient status and considered
on a case-by-case basis. The fluids used in replacement fluid therapy for non-HD burns,
which would likely be appropriate for use in HD injuries if fluid replacement is required,
are described by Settle,80 Brisebois,81 and Thomas et al.82
Sulfur mustard casualties should be kept comfortable and their lesions regularly
cleansed to prevent infections. Limbs may need to be immobilized, as movement of joints
can aggravate existing lesions. Blisters arising on the trunk require protective dressings to
avoid or minimize damage as a result of friction with clothing or bedding. As burning and
itching sensations are typically present after the appearance of erythema is noted, topical
antipruritics are applied (eg, calamine lotion, 0.25% camphor, menthol, corticosteroidal
preparations, and silver sulfadiazine cream). Systemic analgesics and antipruritics may be
indicated, depending on the discomfort level of the patient.
Infection is a significant factor in causing delayed healing of cutaneous HD injuries.
These injuries are covered by necrotic debris, which is a nidus for infection. There is no
consensus, however, on whether intact blisters should be deroofed. Blister fluid from intact
blisters provides a sterile wound covering, but the blisters are fragile and easily ruptured.
Onceblistershavebroken,raggedroofsshouldberemovedandsteriledressingsputinplace
as soon as possible. Wounds should be inspected periodically for signs of infection.
It is generally recommended in military medical manuals to deroof blisters that are
greaterthan1cmindiameter,irrigatingtheunderlyingarea2to4timesperdaywithsaline,
sterilewater,cleansoapywater,orDakin’ssolution.Followingcleansing,theareashouldbe
liberally covered with a topical antibiotic cream (eg, silver sulfadiazine; mafenide acetate;
bacitracin; and triple combination preparations of neomycin sulfate, polymyxin B sulfate,
and bacitracin zinc [Neosporin, Pfizer Inc, New York, NY]). A sterile dressing should then
be put in place. Blisters that have already broken should have their ragged edges removed
and the area irrigated, treated with antibiotic, and dressed with a sterile dressing. Blisters
lessthan1cmindiametershouldbeleftintact,withtheareasurroundingtheblisterirrigated
at least once per day followed by application of a topical antibiotic. A petrolatum gauze
bandage can be put in place over these unbroken blisters, if desired. Any such dressings
should be changed every 3 to 4 days.
Whilethesehandbooksrecommendtheuseofbacitracinandtriplecombinationprepa-
rations following cleansing of deroofed blisters, they do not provide specific application




wounds and the possibility of metabolic derangements. Such problems are not encountered
withtheuseof5%mafenideacetatesolution,whichshouldbeusedinsteadofthe10%cream.
STRATEGIES FOR THE DEVELOPMENT OF IMPROVED THERAPIES
Previous animal studies have shown that surgically aggressive approaches are needed to
prevent or minimize significant cosmetic and functional deficits that result from deep
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HD injury. For the best outcome, deep dermal/full-thickness cutaneous HD injuries re-
quire full-thickness debridement followed by autologous split-thickness skin grafting.45,83
These surgically aggressive approaches to deep HD injuries resulted in the return of
barrier function, skin color, and mechanical properties (hardness and elasticity) to near-
normal levels within 15 days of treatment in a weanling pig model.83 To be successful,
the skin grafts must be placed on a hemostatically secure wound bed, devoid of blood
clots, debris, or necrotic tissue. The recipient bed must have an adequate blood supply to
nourish the skin grafts, and the grafts must be protected from shearing forces, motion,
and mechanical disruption. A variety of modalities is available and may be employed in
achieving initial graft adherence and subsequent acceptance (“take”). These include su-
tures, surgical staples, fibrin glue, tie-over bolsters, compression dressings, and a variety
of antishear dressing techniques. The choice of fixation and dressing technique is deter-
mined by the size and location of the wounds, and the experience and preferences of the
surgeon.
Split-thickness skin grafting was used late in a few cases during the Iran-Iraq conflict
where healing was particularly slow12 and for the late treatment of some poorly healing,
deep injuries sustained in 1992 by a civilian who came across an unexploded artillery
shell from the First World War.72 The NATO Handbook on the Medical Aspects of NBC
DefensiveOperationsstatesthatgraftinghasrarelybeenrequiredinthepastandwhenitwas
attempted,graftacceptancehasbeenpoor.76 Surgicaldetailsofthegraftingproceduresused
are not readily available, and the procedures may not have been optimal. In contrast to this
handbook, Graham et al45 noted equally high graft acceptance rates following either full-
thickness sharp surgical tangential excision or laser debridement using a deep dermal/full-
thickness HD injury model in weanling pigs. In thermal burns management, deep burns
are grafted to promote timely wound closure and improve outcome with minimal cosmetic
and functional deficits. The decision to graft is based on depth of injury. As with thermal
burns, depth of HD injury should be accurately assessed before treatment begins. Reported
long-term effects such as fragile skin and scarring likely indicate that injury depth was not
accurately diagnosed and treatment was not sufficiently aggressive. As with deep thermal
burns, deep HD injuries will require surgically aggressive approaches.
WhilepastHDwound-healingresearchinswinehasconcentratedondeepdermal/full-
thickness injuries, superficial (epidermis only) and superficial dermal injuries may have
greater clinical relevance on the battlefield. Partial-thickness injuries will likely not re-
quire such surgically aggressive approaches (eg, split-thickness skin grafting). Treatment
strategiesforimprovedhealingofpartial-thicknesscutaneousHDinjuryhaverecentlybeen
formulated by a working group of researchers and physicians at government laboratories
in the United States and United Kingdom. The strategies are described below. Research is
underway to experimentally support these strategies and determine which medical devices,
supplies, and pharmaceuticals are most efficacious.
It is important to recognize that for any therapeutic regimen to be successful, a healthy
immunological,84 nutritional/metabolic,85 and psychological86 status needs to be main-
tained. Infections and perturbations in organ function also need to be closely monitored and
addressed as needed.
The ultimate goal is to determine the most efficacious treatment regimen to be applied
in the clinical management of HD casualties. The ideal regimen should return damaged
skin to optimal appearance and normal function in the shortest time. Improved treatment
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will result in a better cosmetic and functional outcome for the patient and will enable the
casualty to return to normal activities sooner.
The pig as an animal model for efﬁcacy testing of candidate treatment regimens
Since human testing with vesicating agents such as HD is unethical, candidate treatment
regimens need to be tested in an appropriate animal model. The animal model of choice
is the pig, due to the similarities between human and porcine skin.87–97 The comparable
histological characteristics of pig and human skin are similarities in epidermal thickness
and composition, epidermal enzyme patterns, epidermal tissue turnover time, lipid content,
characterofkeratinousproteins,pelagedensityandpatternofhairgrowth,dermalstructure,
deposition of subdermal fat, and general morphology.90–92 In addition, pig skin is antigeni-
cally closer to human skin than is rodent skin. A number of human antibodies have been
showntocross-reactinpigskin.98 USEnvironmentalProtectionAgencyguidelinesforder-
mal exposure assessment state that the percutaneous absorption of many compounds in the
pig is similar to that found in humans.93 Dick and Scott90 found that pig skin permeability
to selected lipophilic penetrants was closer to that of human skin than was rat skin. Klain et
al94 concluded that pig skin was a good model for human skin metabolic studies. Meyer et
al95 concluded that among the domestic species, the pig provides the most suitable experi-
mental model for dermatological research on humans. Results from studies of experimental
treatments in porcine models of partial-thickness wound healing have correlated well with
results of clinical studies.91 These findings suggest that the pig is a suitable research animal
to use for predicting cutaneous effects of xenobiotics in humans. Some differences between
humanandporcineskinhavebeennoted,however.Pigslackeccrinesweatglands,92although
hair and sebaceous gland number and distribution are similar.91 Tubular apocrine glands
are present and lie adjacent to hair follicles, and are more numerous than in humans.92 The
subepidermalvascularnetworkislessdensethanitisinhumans;however,thepatternofvas-
cularization in the lower region corresponds to that found in humans.92 In addition, the per-
meabilityofpigskintoHDmaybesignificantlyhigherthanthatofhumanskinundercertain
conditions.96
Pigs have been widely used in vesicant research.10,11,38,45,83,96–109 Weanling pigs have
often been used for their ease of handling during lengthy wound healing studies. They are
small enough to be easily placed under chemical fume hoods during agent exposures and
have a large enough body surface to allow multiple, large (3-cm-diameter) lesions to be
placed on either the dorsum or the ventral abdominal surface. While they do grow during
wound healing studies, functional data (eg, microcutaneous blood flow, skin color) can be
normalized to surrounding unaffected skin83 and morphometric data can be normalized
to total body surface area45 to take this growth into account. The healing process appears
to be optimal in young pigs.92 The healing rate is faster in Yorkshire piglets than in ma-
ture Yucatan miniature pigs,91 and young pigs are highly resistant to contamination and
infection.92 Furthermore, pigs are amenable to habituation and can be trained to allow
noninvasive biophysical skin measurements to be obtained from HD-exposed sites on the
dorsum without the need for restraint or anesthesia.110 Finally, the use of pigs in cutaneous
ulcer and burn wound research is supported by the US Food and Drug Administration.111
Thus, weanling pigs appear to be a suitable model for examining the efficacy of treatment
regimens without significant interference caused by high infection rates or slow healing
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rates.However,theywouldnotlikelybetheidealmodelforstudyingwoundcolonizationor
infection.
While there is no common laboratory animal species, including the pig, that generates
frank blisters, as do humans, HD has been noted to induce microblisters in pigs.10 This lack
of frank blistering is thought to be the result of a diminished superficial dermal vascular
plexus,adenselyarrangeddermis,andlackoflooseareolartissuethatprecludesintercellular
fluid accumulation.92
Immediate treatment of cutaneous sulfur mustard casualties
This section describes the recommendations of the US-UK working group for the imme-
diate treatment of HD casualties. The uses of anti-inflammatory agents, antioxidants, and
occlusive/semiocclusive dressings are discussed. The potential need for replacement fluid
therapy and management of intact blisters are also addressed.
For those patients who are beginning to present with erythema or those who are in
the latent period and suspect an exposure may have occurred, systemic administration of
an anti-inflammatory agent will likely help to decrease the amount of damage ultimately
induced. The pro-inflammatory mediators IL-1β, IL-6, IL-8, and TNF-α are released by
normalhumanepidermalkeratinocytesincultureonexposuretoHD.112 Sulfurmustardhas
also been shown to provoke an edema response and release of IL-6 in 2 different mouse
models.113 Sulfurmustard–inducedinflammatoryresponsesthemselveslikelycontributeto
the severity of the pathology, and numerous animal studies have shown the benefits of pro-
phylactic or therapeutic use of anti-inflammatory agents.43,69–71 There are active programs
researching a variety of nonsteroidal anti-inflammatory drugs (NSAIDs) administered top-




and dosing regimen is the most efficacious in preventing or ameliorating the effects of HD
on skin. It is likely that administration for 2 to 5 days will be required for an NSAID. Topi-
callydeliveredintracellularscavengerssuchas4-methyl-2-mercaptopyridine-1-oxide69 and
dimercaprol69,71 have proved effective in animal experiments in reducing the severity of
HD-induced cutaneous injuries, and concurrent use of one of these agents with an NSAID
may yield the best results (Dr William J. Smith, PhD, US Army Medical Research Insti-
tute of Chemical Defense, Aberdeen Proving Ground, Md, oral communication, 2004). (It
should be noted that mouse skin is very thin and permeable. Any topical agent showing ef-
ficacyinamousemodelshouldalsobetestedinanotheranimalmodelsuchastheweanling
pig.) Corticosteroid anti-inflammatory agents such as hydrocortisone (given systemically
or topically for cutaneous HD injuries)70,71 and dexamethasone (tested in vitro on primary
alveolar macrophages and given topically for ocular HD injuries)114,115 also appear to be
promising therapeutic agents. There are other topical steroidal anti-inflammatory agents of
much greater potency that would likely be very efficacious if used early in the lesion devel-
opment stage, such as betamethasone dipropionate, clobetasol propionate, and diflorasone
diacetate. Superpotent (Class 1), potent (Class 2), and upper mid-strength (Class 3) topical
corticosteroids should be tested for their efficacy in ameliorating HD-induced cutaneous
injury.
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As previously discussed, depletion of GSH and accumulation of endogenous oxidants
and ultimate formation of potent oxidizing species (eg, toxic lipid peroxides) may be con-
tributory factors in HD-induced cytotoxicity.1 Topically applied HD has been shown to
negatively affect antioxidant enzymes in blood cells and body tissues of rats.116 Several
antioxidants have been shown to protect liver and lung from oxidative damage following
inhalation or percutaneous exposure to HD in a mouse model.117 It has been suggested that
administration of antioxidants may be protective and useful.118 Thus, initial antioxidant
treatmentaimedataffectingtheprogressionoflesionsthatisinstitutedduringtheerythema
phase may prove to be of benefit. The effectiveness and role of the interruption of the in-
flammatory cascade by the inclusion of topical and systemic antioxidant agents as well as a
determination of the optimal timing for such therapy are important and intriguing avenues
for investigation.
Placement of an occlusive or semiocclusive dressing will likely prove to be helpful
in promoting autolytic debridement and preventing desiccation. Debridement will play a
central role in improving the healing of cutaneous HD lesions, and beginning the process
early may be beneficial. How soon following exposure these dressings can be applied
remains to be determined. While maintaining a moist environment has long been known
to facilitate wound healing,119–122 caution needs to be observed since very early occlusion
that builds up moisture levels in the skin will exacerbate the lesion. In addition, there is a
period following exposure to sulfur mustard at which off-gassing of unbound HD occurs
following a vapor104 or liquid exposure in weanling pigs (J. S. Graham et al, unpublished
data, 2001). The existence of a reservoir of unbound HD in human skin was previously
discussed. These studies have suggested that off-gassing can continue for 24 to 36 hours,
given a large exposure. Limiting the escape of this unbound HD by using an occlusive
dressing may exacerbate the lesion. Placement of any occlusive dressing should probably
be postponed for at least 24 hours following exposure. Keeping clothing off the exposed
area, thereby not allowing vapors to build up, may also be of benefit.
The potential need for replacement fluid therapy (RFT) and caution in avoiding over-
hydration was previously discussed. Requirements for RFT can be studied experimentally.
A scientific study using an appropriate animal model needs to be conducted to determine
whether body weight and percent TBSA affected should be taken into consideration when
tryingtodeterminethetotalvolumeoffluidrequired.Itisalsoimportanttodeterminewhich
fluids are most appropriate, what infusion rates are needed, and when to commence RFT.
Usinginstrumentedpigs,largeareasofinjurycanbeinduced,followedbyclosemonitoring
overtimeofimportantphysiologicalparameters.TheeffectsofdifferentRFTprotocolscan
then be determined. To generate large TBSA injuries, exposures with partial-body vapor
chambers can be used. Alternatively, liquid HD can be diluted to volumes greater than that
allowedundercurrentsuretyregulationsandfast-wickingmaterialusedtospreadtheliquid
out over a large area. Previous research has enumerated a number of stable vehicles that are
suitable for cutaneous exposure with liquid HD.108
Management of casualties presenting with intact blisters varies according to the sit-
uation and level of care. Avoidance of infection is paramount so that the depth of injury
does not increase. Small blisters should not be disrupted until deroofing can be done under
controlled conditions. Larger blisters that are already flaccid may require deroofing or col-
lapsing under sterile conditions. Current data does not permit recommendation of a single
best approach. Once the necessary conditions and skills are reached, intervention should be
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more aggressive, with the dual goals of avoiding wound infection and optimizing recovery.
As detailed below, aggressive management of the cutaneous HD injury, as opposed to that
conducted on thermal or toxic epidermal necrolysis blisters, will require removal of the
wound edges into normal-appearing skin along the periphery of the lesion and debride-
ment of the base of the blister through the damaged BMZ into healthy dermis. Accurately
determining depth of injury will influence this step. These patients will also require pain
management and close observation for the systemic effects of HD exposure. Absence of
thorough removal of damaged tissues will greatly slow healing and will enhance scarring
and contracture in all but the most minor injuries.
For patients presenting with intact frank blisters, it may be beneficial to aspirate the
blister fluid with a sterile needle and syringe and allow the roof of the blister to act as
a sterile dressing until a physician can remove it. Reattachment of blister roofs has been
noted to occur in the treatment of vitiligo via epidermal grafting using the tops of suction
blisters123,124 and in experimental suction blisters in humans following aspiration of blister
fluid.125 The roofs of HD blisters, however, are not expected to reattach to the blister floor
owingtoHD-induceddamagetobasalcellsandBMZcomponents.Sloughingisexpectedto
eventuallyoccur.ForpatientspresentingwithrupturedHD-inducedblisters,carefulremoval
of the blister roof with scissors, application of an antibiotic ointment, and placement of a
sterile dressing is warranted. For both of these scenarios, more complete debridement will
be necessary for large lesions, as described later.
Treatment of established partial-thickness lesions: overview of the approach
TheremainingsectionsofthisreviewdescribetherecommendationsoftheUS-UKworking
group for the treatment of established partial-thickness cutaneous HD lesions. The general
approachthatisbeingtakenistoperformadequatedebridementofpartial-thicknessinjuries,
then treat the lesions like chronic cutaneous ulcers or partial-thickness thermal burns using
contemporary medical approaches.
Before treatment can begin, the extent and severity of cutaneous HD injuries must
be determined. Following assessment of injury and deroofing of frank blisters, adequate
wound debridement needs to be performed, followed by 1 or more treatment adjuncts.
Examples of adjuncts under consideration are dressings, growth factors, skin substitutes,
topical nutritional support, and Vacuum Assisted ClosureTM (V .A.C.
  R), Kinetic Concepts,
Inc (KCI), San Antonio, Tex.
Injury assessment
Before HD injuries can be appropriately treated, assessment of the injuries must be made.
Totalbodysurfaceareaoftheinjuriesshouldbeestablishedanddepthofinjurydetermined.
Total body surface area can be determined using Wallace’s Rule of Nines and the Lund and
Browder chart for estimating burn severity, as previously discussed.77,78 Determination of
injury depth is a much more challenging task. Accurate depth assessment is important
because it dictates how aggressive treatment needs to be to minimize or prevent cosmetic
and functional deficits.
Inthermalburns,depthofinjuryistypicallyassessedbyphysicalexamination.Surface
appearance, the pinprick test to assess pain, the “blanch-capillary return test” to evaluate
microcirculation,andsurfacetemperaturedifferencebetweenburnedandunburnedskinare
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often used in diagnosis of depth.126 Using these methods, diagnosing very superficial and
very deep burns is relatively easy for the experienced burn surgeon. Burns of intermediate
depth are often problematic in determining the need for grafting. Determining depth of HD
injuriesismorechallenging.First,thefullextentofcutaneousinjurycantakeseveraldaysto
manifest. Second, superficial appearances do not accurately predict depth of injury or need
for grafting. While the presence of blisters in thermal burns is generally associated with
superficialdermalinjuries,blisteringinHDinjuriescanoccurindeepdermal/full-thickness
injuries because of the unique nature of the agent and the unique progression of the injury.
Noninvasively examining cutaneous blood flow using available bioinstrumentation
can greatly assist the physician in determining depth of injury. Laser Doppler perfusion
imaging and indocyanine green fluorescence imaging may prove to be very valuable tools
inprognosticatingoptimalwoundhealingofboththermalburnsandcutaneousHDinjuries.
Laser Doppler flowmetry and laser Doppler perfusion imaging (LDPI) have been used
for prolonged, noninvasive monitoring of tissue viability and wound healing and for the
assessment of peripheral vascular disease, inflammation, ischemia, reperfusion, skin graft
acceptance(take),andburndepth.127–142 LaserDopplerperfusionimagingmayproveuseful
in delineating the areas of HD damage that need to be debrided, thereby avoiding areas with
sufficient blood flow. Brown et al101 found that laser Doppler perfusion images of vesicant
vapor burns on the backs of swine correlated well with histopathological findings (throm-
bosis and necrosis of subepidermal capillaries) between 1 hour and 7 days postexposure
and suggested that clinical management decision making for treatment of early vesicant
burns could be aided by LDPI. Chilcott et al102 used several noninvasive bioengineering
methodstomonitorwoundhealinginalargewhitepigmodelfor7daysfollowingexposure
to HD and Lewisite vapors. They concluded that while reflectance colorimetry and TEWL
measurements could provide quantitative, noninvasive methods for determining efficacy of
candidate treatment regimens, neither is comparable to the prognostic capabilities of LDPI.
Graham et al83 found LDPI to be useful in examining blood flow in grafted and ungrafted
sites following treatment of deep dermal/full-thickness liquid HD injuries in a weanling
swine model (Fig 1). Laser Doppler perfusion imaging is currently rather time consum-
ing if there are multiple sites to be evaluated and/or large images to be collected at high
resolution. The length of scanning procedures could be decreased by increasing scanning
speed(thusdecreasingfluxresolution),decreasingthesizeofthescanarea,and/ordecreas-
ing the number of lines scanned within the scanning area (scan resolution). Improvements
inthetechnologythatwillspeedupLDPIwithoutcompromisingimageresolutionarebeing
developed.
Indocyanine green fluorescence imaging has also shown promise in determining burn
depth based on microcutaneous blood flow. It is a minimally invasive procedure that
requires the placement of an intravenous line. Indocyanine green (ICG) is US Food and
Drug Administration–approved for use in humans to determine cardiac output, hepatic
function and blood flow, and for ophthalmic angiography. The fluorescence of intravenous
ICG has been shown to estimate burn depth in small animals.143 In contrast to fluores-
cein fluorescence,144 ICG fluorescence is capable of distinguishing superficial and deep
partial-thickness burns from full-thickness burns. The fluorescence intensity of ICG de-
creases exponentially with burn depth for burns of similar age.145 Indocyanine green fluo-
rescence was used to estimate burn depth in a porcine model.146 An imaging system with a
diagnosticalgorithmwasdevelopedattheWellmanLaboratoriesofPhotomedicine,Boston,
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Figure 1. Laser Doppler perfusion imaging of deep dermal/full-thickness sulfur mustard injuries
inaweanlingpigmodel,8daysaftersurgery.Siteswereexposedtoliquidsulfurmustardfor2hours.
Surgery was conducted 48 hours after agent exposure. The site on the left was untreated. The site in
the center underwent full-thickness sharp surgical tangential excision followed by autologous split-
thickness skin grafting. The site on the right underwent full-thickness laser debridement followed
by grafting. Blue areas indicate low blood flux, red areas high blood flux and yellow/green areas
intermediate blood flux. Analyses indicated poor blood flow in the untreated area and adequate
blood flow in the grafted areas. Graft acceptance rates were equally high between both methods of
debridement. Regardless of surgical approach, blood flux levels remained approximately 50% to
60% of normal tissue throughout a 36-day postsurgical observation period.83
Mass, that accurately diagnosed burns that healed within 21 days with minimal scarring
from those that took longer to heal by secondary means. Measurements were made on
burns created 2, 24, 48, and 72 hours prior to imaging. The algorithm was shown to be
dependent on the age of the burn but not on location. This technology showed promise in
plastic surgical applications147,148 and for accurate determination of thermal burn depth in
humans.147,149 Indocyanine green fluorescence imaging also shows promise in diagnosing
depth of HD injury (Fig 2; J. S. Graham et al, unpublished data, 1999). The advantage that
this technology has over LDPI is the speed of image capture. Multiple images over large
areas can be captured in a relatively short period of time. Images are typically collected 5
to 10 minutes after ICG injection to allow uptake and distribution. The dye is then excited
(eg,780nm)andtheresultantfluorescenceemission(eg,825nm)immediatelycapturedand
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Figure 2. Indocyanine green fluorescence imaging of cutaneous sulfur mustard injuries in a wean-
ling pig model, 48 hours after agent exposure. The fluorescence of intravenous indocyanine green
has been shown to estimate thermal burn depth in small animals. Indocyanine green fluorescence is
capable of distinguishing superficial and deep partial-thickness thermal burns from full-thickness
burns.Thefluorescenceintensityofindocyaninegreendecreasesexponentiallywithburndepthfor
thermal burns of similar age. Indocyanine green is a nontoxic and rapidly excreted tricarbocyanine
dyethatisstronglyboundtoserumproteinsandleaksfrompatentvesselsafteraninjury-inducedin-
crease in vessel permeability. Mean fluorescence levels within superficial injuries are much greater
than those in surrounding normal tissue. In deep injuries where blood vessels are occluded, very
little dye leaks into the extravascular space; hence mean fluorescence levels within deep injuries
are much less than those in surrounding normal tissue. Shown here on the left, a deep dermal/full-
thickness injury was generated after exposure to liquid sulfur mustard for 120 minutes, showing
very dark patches in the center of the injury, surrounded by a ring of hyperemia. The center lesion
is a superficial dermal injury that was generated after a 2-min exposure to sulfur mustard, showing
a significant amount of fluorescence indicative of patent blood vessels. The lesion on the right is
of intermediate severity. (J. S. Graham et al, unpublished data, 1999)
saved by a computer and analyzed for burn-to-normal skin fluorescence ratio. Indocyanine
green binds strongly to plasma globulins, limiting both extravasation within burn-injured
vascular epithelia and extravascular transport to areas nearby.145 Large signals are thought
to be the result of vasodilation and hyperemia, and smaller signals are thought to be at-
tributable to vascular occlusion and edema.143,145 With this technique, live streaming video
can also be captured immediately after injection, allowing the physician to watch the dye
flowing through viable tissue and around nonviable tissue in real time.
It is of fundamental importance that any noninvasive or minimally invasive technique
used to assess lesion severity be fully validated in order that results may be correctly
interpreted. For example, a recent study has demonstrated that TEWL may not necessarily
correlate with skin “barrier function.”150
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Debridement
Experimental approaches to vesicant wound debridement have included powered




suturing of the skin defect to be effective in decreasing healing time of HD vapor lesions
in guinea pigs. Powered dermabrasion, pulsed CO2 laser ablation, and erbium:yttrium-
aluminum-garnet (Er:YAG) laser ablation have been shown to accelerate the rate of heal-
ing of full-thickness cutaneous Lewisite vapor burns in swine without the need for split-
thickness skin grafting.107,109 Eldad et al152 found that excimer laser ablation and debrase
(Debridase, MediWound Ltd, Yavne, Israel) enzymatic debridement were efficacious in
improving the healing of partial-thickness nitrogen mustard burns in a guinea pig model.
Because of positive results achieved by laser and enzymatic debridement of vesi-
cant injuries, our future research efforts will concentrate on the use of usthese methods
to debride partial-thickness cutaneous HD injuries prior to the application of treatment
adjuncts. The treatment regimen that is found to be most efficacious in the pig will ul-
timately be recommended for use in treating human casualties. Because humans form
frank blisters, unlike the pig, these regimens would follow deroofing of any frank blisters
present.
LASER DEBRIDEMENT OF CUTANEOUS VESICANT WOUNDS
Laser debridement of cutaneous vesicant wounds has proven to be an effective method of
improving the rate of wound healing in pig models. Graham et al100 showed that viability,
thickness, and organization of the epidermis were all significantly improved by partial-
thickness pulsed CO2laser debridement of small, mild to moderately severe cutaneous HD
vaporinjuries.Laserdebridementfollowedbyskingraftingwasasefficaciousinimproving
thewoundhealingofdeepHDburnsassharpsurgicaltangentialexcisionfollowedbygraft-
ing (the gold standard in human deep dermal/full-thickness thermal burns medicine).45,83
Middermal debridement by sharp excision or laser ablation without grafting produced less
desirable results but was better than no treatment.45,83 A 4-fold improvement in reepithe-
lialization of Lewisite injuries was achieved at 1 week following laser dermabrasion, with
almost 100% reepithelialization by 3 weeks.109 It is not apparent why these full-thickness
Lewisite injuries (10 cm2) did not require grafting, as did HD injuries (12.6 cm2)45,83 or as
would a full-thickness thermal burn. There are differences in biochemical action and rates
of spontaneous reepithelialization between Lewisite and HD injuries.109 Further studies
need to be conducted to fully examine the comparative healing of deep Lewisite, HD, and
thermal injuries.
Laser debridement offers additional benefits including hemostatic control during
surgery, minimal risk of exposure to aerosolized pathogens, and time efficiency. Another
major advantage to the use of lasers is the ability to control the amount of normal perile-
sional skin that is removed. Eldad et al152 noted that it is technically difficult to control the
amount of tissue to be removed by surgical tangential excision and that laser ablation of
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nitrogen mustard burns in a guinea pig model enabled both controlling the amount of tissue
to be removed and minimizing blood loss. Minimizing the amount of tissue removed will
be of a cosmetic benefit to the patient.
Types of lasers available
Pulsed CO2 lasers have been used for a variety of dermatological applications, including
skinresurfacing,153–155 excisionofburneschar,156–159 preparationofadequategraftbeds,160
and conservative ablation of skin lesions.161 They are designed to promote rapid healing
by minimizing laser-induced residual thermal damage,153,154,160,162–166 and offer precise,
micrometer-depth removal of tissue.166 They vaporize tissue rapidly and efficiently, with
minimal blood loss.159,166,167 However, because of the low average power available from a
pulsedlasersystem,theselasersmaybeinefficientwhileperformingfull-thicknessdebride-
ment of deep burns or while debriding burns covering large body surface areas. Continuous
wave (cw) lasers can be quite efficient in removing tissue but tend to create significant
amounts of thermal damage, sometimes creating more damage than the initial burn being
treated. Domankevitz and Nishioka167 demonstrated that under appropriate conditions, a
scanned cw CO2 laser could ablate tissue with a zone of residual thermal injury less than
200 µm, making it useful for cutaneous surgery and debridement of burn wounds prior to
skingrafting.Residualthermaldamageofcwlaserscanbeminimizedifthelaserisscanned
over the surface rapidly enough that the amount of time the laser spends on any 1 point
mimics a short laser pulse.167,168 Use of such lasers has proven efficacious in pigs45,169 and
humans.170 Glatter et al169 usused a prototype cw CO2laser in a thermal burn model in pigs
and found that long-term scarring, based on Vancouver scar assessments, was equivalent
at 6 months postsurgery in both laser-ablated + grafted and sharply excised + grafted
burns. In addition, they noted no significant difference in engraftment rates between the 2
methods of debridement. Graham et al45 had similar success in engraftment rates using this
same laser to treat HD injuries in pigs. In an initial clinical trial, Sheridan et al170 used a
similar, commercially available system to perform full-thickness ablations of thermal burns
in children. They found that no bleeding occurred in laser-ablated sites, that engraftment
rates for both laser-ablated sites and sharply excised sites were equally high, and that there
were no significant difference in Vancouver scar scores at an average follow-up of 32.0 ±
5.2 weeks.
There are a number of lasers manufactured in the United States, Canada, and Europe
thatcouldbeconsideredforroutinedebridementofvesicantinjuries.AclandandBarlow171
have provided a review on the current uses of lasers in dermatological practice and a list of
the types of lasers used for specific procedures. They list CO2 and Er:YAG lasers as being
the most appropriate for cutaneous resurfacing. While rapid-scanning, high-powered cw
CO2 lasers would provide time-efficient ablation of damaged tissue,45 they are no longer
commerciallyavailable.PulsedCO2 laserssuchastheUltraPulse(LumenisInc,SantaClara,
Calif) are in common use in dermatology and plastic surgery and have proved effective
in improving wound healing of cutaneous vesicant injuries.100,109 Er:YAG lasers are also
commercially available and have been used for a wide variety of procedures, ranging from
facialresurfacingtoburndebridement.171–175Theyhavebeenshowntobeparticularlyuseful
in the debridement of partial-thickness burns175 and in the management of deep Lewisite
injuries.109 Unlike the Gaussian beam profiles created by CO2 lasers, Er:YAG laser beams
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tend to be uniform and produce uniform depths of ablation.175 One commercially available
unit, the Sciton PROFILE (Sciton Inc, Palo Alto, Calif), can be configured as a high-
powered, dual-mode long-pulse Er:YAG laser that allows independent control of both depth
of coagulation and depth of ablation. This versatility would be very advantageous to any
clinic or hospital that treats burns and a variety of dermatological disorders. Er:YAG lasers
will play a central role in future HD wound healing studies at our facilities.
ALTERNATIVE METHODS OF DEBRIDEMENT UNDER CONSIDERATION
There are alternatives to using a laser to debride vesicant injuries. Sharp surgical tangen-
tial excisions and powered dermabrasion have proved effective.45,99,106,107,152 Curettage,
cryotherapy, larval therapy, and enzymatic debridement may be effective, lower-cost alter-
natives.
Sharp surgical tangential excisions have been effective in the treatment of sulfur
mustard45 andnitrogenmustard152 injuries.Powereddermabrasionhasbeenshowntospeed
upthereepithelializationprocessofcutaneoussulfurmustard99,106 andLewisite107 injuries.
There are drawbacks with this method, however, including lack of uniform depth control
and risk of aerosolizing pathogens.
Scraping, using dermal curettes, may be a viable option for removing desiccated ma-
terial from the surface of the skin. Cryotherapy using ice, liquid nitrogen, or Peltier coolers
may also be efficacious if applied early. The therapeutic effects of cooling pig skin soon
afterexposuretoHDvaporhasrecentlybeenreported.176 Itmaybepossibletosuperficially
freezeHDlesionsbeforetheyproceedtovesication,therebyretardingtheactivityoftheHD
and progression of the lesion. The frozen tissue could then be removed using appropriate
means, and the wound bed dressed with an antibiotic and sterile dressing until healed. Cau-
tion would have to be observed in the length of time the cooling agent is in direct contact
with the skin and its potential to induce hypopigmentation taken into consideration. Finally,
the use of larval therapy (maggots), while unconventional, has undergone a renaissance
in the past few years and has proven to be very effective in debriding and improving the
healing rate of hard-to-heal wounds (eg, chronic leg and foot ulcers).177–184 The success
of this approach may warrant study as a possible treatment of small TBSA sulfur mustard
injuries.
AfinalalternativeunderconsiderationfordebridementofHDinjuriesisenzymaticde-
bridement. These enzymes are categorized as proteolytics, fibrinolytics, and collagenases,
and are designed to dissolve necrotic tissue from wounds.185 They are often used to debride
chronic wounds (eg, decubitus ulcers, venous stasis ulcers, arterial insufficiency ulcers,
diabetic foot ulcers). Many have been found to be safe and effective in removing devital-
ized tissue and accelerating healing in burns.186–193 Any burn eschar present is typically
cross-hatched to allow the agent to penetrate into the wound. Other agents, such as the
bacterial proteolytic enzymes streptokinase and streptodornase, have given disappointing
results in deep burns because they do not break down the collagen that separates vital from
nonvital tissue.194 Use of fibrinolysins may impair wound healing of HD lesions, as fibrin
is an early matrix protein that is essential for wound healing. In addition, fibrinolysins are
typically combined with deoxyribonuclease (DNase) and as such will also digest DNA in
the dividing fibroblasts, which play a role in healing.185 Some effective enzymes have pro-
duced better results than others, with enzyme concentration, skin moisture level, and the
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presence of certain antibacterial agents affecting results. Secondary dressings are needed
to keep the wound moist and to allow these agents to work.185 Klasen194 offers an ex-
cellent review of the use of enzymatic debridement agents in burns. The most popular
and effective agents on the market today are collagenases (eg, Collagenase Santyl oint-
ment, Ross Products Division, Abbott Laboratories Inc, Columbus, Ohio) and papain/urea
combinations (eg, Accuzyme and Panafil, Healthpoint Ltd, Fort Worth, Tex; and Gladase
Papain-Urea Debriding Ointment, Smith & Nephew Inc, Largo, Fla). In addition, a promis-
ing proteolytic enzyme extracted from the stem of the pineapple plant is in Phase II clinical
trials in the United States and Europe for the treatment of deep partial- and full-thickness
burns (Debrase Gel Dressing, MediWound Ltd, Yavne, Israel). Enzymatic debridement of
HD injuries is a promising and cheaper alternative to laser debridement, albeit more time





Burn wound sepsis and bacteremias have been noted in burn patients undergoing
enzymaticdebridement.185,194 Concomitantuseofatopicalantibioticthatdoesnotinterfere
with the action of the enzyme under study may be warranted as a preventative measure.
EXTENT OF DEBRIDEMENT REQUIRED
In addition to vesication and death of epidermal keratinocytes, HD exposure results in
sublethal damage to keratinocytes along the periphery of the gross lesion. Damage to the
basement membrane zone and underlying collagen in the papillary dermis has also been
noted. Deroofing frank blisters followed by timely removal of this adjacent and subjacent
damage will likely improve the rate of reepithelialization.
Nonlethal damage is clearly noted at the periphery of cutaneous HD lesions and has
been reported previously.11,105,195 Nikolsky’s sign,196 characterized by separation and loss
of the epidermis from the dermis when the skin is pressed with a sliding or twisting mo-
tion, has been demonstrated in weanling pig skin following HD vapor exposure.11,195
These weakened areas of the dermal-epidermal junction occurred along the periphery
of the gross lesions and are indicative of sublethally damaged basal cells and/or altered
proteins of extracellular matrices of the BMZ. Sublethally injured cells at the periph-
ery of an HD lesion and in hair follicles and other adnexal structures may be partly
responsible for the slow rate of reepithelialization seen in these injuries. Rice et al106
suggested that the level of damage to cellular DNA at the margins of HD lesions may
be sufficient to delay or prevent effective replication of those keratinocytes. Removal
of these sublethally damaged keratinocytes at the margins of the lesions by debride-
ment beyond the visible borders of the lesion will likely speed up the reepithelialization
process.
As previously discussed, HD induces damage to the BMZ at the level of the lamina
lucida.5,39 The floor of the blister retains portions of the damaged BMZ and needs to be
removed to provide an adequate scaffold over which keratinocytes feeding the reepithelial-
ization process can migrate. Thus, at minimum, debridement needs to proceed down into
the papillary dermis after removal of the blister roof. Beyond the BMZ, dermal collagen
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itself is affected by HD exposure and can itself impede the wound healing process.97,106,197
Brown and Rice197 reported coagulation and hypereosinophilia of the papillary dermis in
Yucatanminipigskin12to24hoursfollowingsaturatedHDvaporexposure,withthedeeper
reticular dermis unaffected. Rice et al106 and Lindsay and Rice97 suggested that following
exposure to HD, papillary dermal collagen is altered and may no longer function normally
as a healthy scaffold over which epidermal cells can migrate.
The question of how deep to debride needs to be addressed. Ablative lasers that create
less than 160 ± 60 µmo fresidual thermal damage permit optimal skin graft take and
healing.160 Domankevitz and Nisioka167 concluded that lasers that induce residual thermal
damage zones of less than 200 µm are useful for cutaneous surgery and burn wound
debridement prior to skin grafting. Lam et al109 were able to improve wound healing of
full-thickness cutaneous Lewisite injuries in pigs by partial-thickness laser debridement.
Graham et al45 were also able to improve wound healing of deep cutaneous HD injuries in
pigs by partial-thickness debridement without grafting, albeit not to the extent attained by
full-thickness debridement followed by grafting. These studies thus indicate that retaining
some amount of damaged dermal tissue does not significantly impede wound healing.
Complete debridement of partial-thickness injury, therefore, will likely not be required.
Debridement of partial-thickness HD injury into the papillary dermis or upper reticular
dermis will likely be adequate.
Dressings
Following wound debridement of HD injuries, an appropriate dressing will be needed to
promote moist wound healing. Beneficial effects of such dressings include prevention of
tissue dehydration and cell death, accelerated angiogenesis, increased breakdown of dead
tissue and fibrin (eg, pericapillary fibrin cuffs), significant reduction in pain, and poten-
tiation of the interaction of growth factors with their target cells.122 Helfman et al119 and
Singhaletal185 haveprovidedoverviewsofthevarioustypesofocclusiveandsemiocclusive
dressings. Hydrocolloids, hydrogels, foam dressings, alginates, and transparent film dress-
ings are commercially available from a large number of manufacturers. As foam dressings
and alginates are designed to control moderate to heavy exudates, they will likely not be
needed for covering debrided cutaneous HD injuries. Silver impregnated dressing mate-
rials may be of great potential benefit in treating these wounds owing to their antimicro-
bial efficacy198–200 and demonstrated ability to enhance rates of reepithelialization.201,202
A number of these dressing materials are currently employed in burn and chronic wound
care, while other more advanced silver dressings are in various stages of development.
Thus, research on finding the most appropriate dressing during wound healing of these
lesions should concentrate on hydrocolloids, hydrogels, thin films, and silver-impregnated
dressings.Testingtheseproductsinapigmodelshouldbeadequate,sincesimilarresponses
to occlusive and semiocclusive dressings on wound healing have been noted in pigs and
humans.203
Weak attachment of the neoepidermis to the underlying dermis has been noted in
human HD casualties44 and experimentally exposed weanling pigs (J. S. Graham et al,
unpublished data, 2004). Once the lesions have fully reepithelialized, protective dressings
may be needed to avoid or minimize damage as a result of friction with clothing or bedding.
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Growth factors
During cutaneous wound healing, growth factors play dominant roles in regulating cell pro-
liferation, differentiation, and synthesis of extracellular matrix.91 Epidermal growth factor
(EGF), transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF),
insulin-like growth factor (IGF), keratinocyte growth factor (KGF), hepatocyte growth
factor (HGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and fibrob-
last growth factors (FGFs) play important and critical roles in the healing of cutaneous
wounds.203–241 Reviews of the effects of these growth factors on wound healing have been
previously published.203–208 Improved wound healing has been reported for topical applica-
tions of EGF,203–220,222,223 PDGF,203–208,214,219,224−229 KGF,206,207,231−233 and IGF-I.235,236
There have been some negative reports on the effectiveness of EGF221 and KGF230 in im-
proving wound healing of experimental split-thickness skin wounds in humans and esoph-
agogastric anastomotic wounds in rats, respectively. Epidermal growth factor has been
shown to improve the healing of graft donor sites,210 corneal burns,217,220 and cutaneous
burns,218,219 whereas PDGF and KGF have been shown to improve the healing of burns219
and skin-grafted lesions.224,233
Human leptin is a 146–amino acid residue, nonglycosylated polypeptide involved in
body weight regulation. It is released from white adipose tissue and exerts its effect via
receptors in the hypothalamus. While not a growth factor per se but rather characterized as
a satiety-regulating cytokine, leptin has been shown to be a potent mitogenic stimulus to
keratinocytes during skin repair.237,238
Resultsfromthesereportssuggestthattopicalapplicationofhealing-enhancingfactors
aloneorincombinationmaybebeneficialinimprovingthewoundhealingofcutaneousHD
injuries following wound debridement. When to commence such treatment following agent
exposure needs careful consideration and experimental testing. During the early phases
of wound healing, chemokines and cytokines regulate the chemotaxis and activation of
inflammatorycells,alongwithsynthesisofproteasesandproteaseinhibitors.91 Earlyappli-
cation of growth factors would be ineffective in a milieu of proteases. Application of such
growth factors or combinations thereof will likely require a delay of 3 to 7 days following
HD exposure until the inflammatory response has subsided. Concomitant use of protease
inhibitors or a dressing that binds matrix metalloproteases and protects growth factors
(eg, PROMOGRAN∗ Matrix Wound Dressing, Johnson & Johnson Wound Management
Worldwide, Somerville, NJ) may be necessary. A number of these growth factors are com-
mercially available for efficacy testing in animal models (EGF, PDGF, leptin). Of these
3, only PDGF has been approved for human use by the US Food and Drug Adminis-
tration. Recombinant human EGF (β-urogastrone) is available from Roche Diagnostics
Corp, Indianapolis, Ind. Regranex Gel, a recombinant human PDGF-BB, is available from
Johnson & Johnson Wound Management Worldwide, Somerville, NJ. Recombinant hu-
man leptin is available from R&D Systems Inc, Minneapolis, Minn. Amgen Inc (Thousand
Oaks, Calif) has recently completed Phase III clinical trials of a recombinant human KGF
(Palifermin) that significantly reduces the duration and incidence of radiation- and
chemotherapy-induced oral mucositis.
In addition to these growth factors, topical application of extracellular matrix compo-
nents such as fibronectin, which supports fibroblast, keratinocyte, and endothelial cell ad-
hesion and movement,242,243 may be of benefit following wound debridement. Fibronectin
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can serve as a template for collagen deposition242 and is a key component of the pro-
visional matrix during wound repair.243 Exogenous application of intact fibronectin has
been shown to be beneficial in helping to close human skin and corneal wounds.244 The
ability of keratinocytes to spread on fibronectin may require the presence of serum or
epibolin/vitronectin.244 Addition of another adhesive glycoprotein, laminin, may actually
be detrimental to the reepithelialization process. When human keratinocytes are placed in
apposition with collagen, they attach and begin migrating.244 This migration is inhibited
by the addition of laminin, which acts as a major cell adhesion factor for keratinocytes.
Laminin 5 has been shown to inhibit human keratinocyte migration and strongly promotes
keratinocyte attachment.244 It is believed to anchor the keratinocytes to the substratum, via
α3β1-integrin receptors.244
Skin substitutes
Skin substitutes may provide an excellent temporary wound dressing for debrided HD
injuries. Permanent wound closure can only be achieved by spontaneous reepithelialization
or by the provision of autologous skin by means of skin grafting. The use of skin substitutes
to temporarily restore the multiple functions of normal skin may be of substantial benefit
in the management of cutaneous HD injuries.
Foraskinsubstituteapplicationtobesuccessful,thesameconditionsrequiredforsuc-
cessful autograft “take” must be created and maintained. The selection of the most suitable
and effective temporary skin substitute will require a critical assessment of its comparative
attributes when applied to HD wounds as well as the issues of cost, ease of use, availability,
andconsistencyofresults.Skinsubstitutesarewidelyusedinhumanthermalburnsmanage-
ment and can be (1) temporary or permanent; (2) epidermal, dermal, or composite; and (3)
biologicorsynthetic.245–253 Theyhavealsobeenshowntobeeffectiveinspeedinguptimeto
closure of chronic leg and foot ulcers,254–269 surgical excision sites,269 and partial-thickness
donor sites.269 They may be a source of growth factors and are generally semiocclusive in
nature. They can provide barrier function; add tensile strength to the wound; are generally
flexibleandpliable;markedlyreducepain,inflammation,anddrainage;andprovideamoist
woundhealingenvironment.Theydonotcontroldeepbacterialinfections;cansealbacteria
in; and, being a biologic, they can transmit infection. Hence, the wound surface must not be
infectedforapplicationofaskinsubstitute.Anumberofskinsubstitutesareavailableonthe
market and should be tested for their efficacy in improving wound healing of cutaneous HD
injuries. Marketed products currently under consideration include (1) living bilayered skin
substitutes (APLIGRAF [Organogenesis Inc, Canton, Mass], designed for the treatment of
venous leg ulcers and diabetic foot ulcers; and OrCel [Ortec International Inc, New York],
designed for the management of split-thickness donor site wounds and for the treatment of
epidermolysisbullosa),(2)bilayeredcompositesconsistingofasyntheticepidermalanalog
and a biologic (collagen-based) dermal analog (TransCyte [Smith & Nephew Inc, Hull,
United Kingdom] and Biobrane [Bertek Pharmaceuticals Inc, Morgantown, Wva], both
designed for partial-thickness wounds), (3) complex weaves of biopolymers that produce
a thin protective membrane (Silon-TSR [Bio Med Sciences Inc, Allentown, Pa], designed
for use on partial-thickness burns, donor sites, and laser-resurfaced skin), and (4) acellu-
lar dermal matrices designed to aid in the natural healing of partial-thickness injuries of
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limited depth (SkinTemp, BioCore Medical Technologies Inc, Silver Spring, Md). Perma-
nent skin substitutes that are designed for treating deep injuries and require application of a
thin epithelial autograft will likely be inappropriate for use in treating partial-thickness
HD injuries (eg, AlloDerm [LifeCell Corporation, Blanchburg, NJ] and INTEGRA
dermal regeneration template [Integra LifeSciences Holdings Corporation, Plainsboro,
NJ]).
Cryopreserved and glycerol-preserved cadaver skin has been used as a temporary
dressing in the treatment of burns for a number of years.270–277 Similarly, xenografts from
av ariety of animal species, especially pig, have been used as temporary cover to treat
burns.278–280 While pig skin is antigenic and would ultimately get sloughed, portions of
the dermis may become incorporated in a healed wound and elicit an unwanted granular
response.278
Cultured epithelial allografts and autografts have been used for about 2 decades
as a treatment for chronic ulcers and thermal burns.248,281–312 Keratinocytes can be har-
vested from skin biopsies and grown to confluence by the method originally described by
Rheinwald and Green.313 Large amounts of stratifying epidermis can thus be grown in the
laboratory in short periods of time and used to restore defects in the epidermis.314 Such
grafts can be used immediately or cryopreserved and used at a later date. In addition to
their usefulness in improving the healing of deep ulcers and burns, they have shown ef-
ficacy in improving the rate of reepithelialization of partial-thickness burns286,290,300 and
split-thickness skin graft donor sites.289,291,307 There is no evidence that cultured allografts
survive permanently on the wound bed.289 Kaawach et al286 showed that allografted cells
were not present between 8 and 100 days postgrafting and suggested that the newly formed
epithelium was of host origin. Cultured keratinocyte allografts speed healing by providing
coverandproducinggrowthfactorsandextracellularmatrixproteins.291 Becausethesecov-
erings can be produced in large quantities and would thus be more readily available than
cadaver skin, their application in the treatment of debrided partial-thickness HD injuries
should be considered. Cultured epidermal autografts (CEAs) would be safer to use, from
the perspective of disease transmission, and would not require donor-screening procedures.
They do, however, require small punch biopsies to be collected from the patient and a lag
time of about 2 weeks to grow the graft material. Several laboratories in the United States
perform this service for their local burn centers (eg, Living Skin Bank, University Hospi-
tal, SUNY, Stony Brook, NY). Genzyme Corporation (Cambridge, Mass) has shown that
CEA (Epicel) can be commercially produced. Despite their theoretical usefulness, CEAs
are rather limited in their clinical effectiveness because they are unable to withstand even
very low levels of bacterial wound contamination and do not provide a durable epithelial
surface. Wounds covered by this modality are unstable and are subject to frequent epithelial
disruptionasaresultofminormechanicaltrauma.Durabilityhasbeenincreasedbyplacing
the CEA on a scaffolding of widely meshed autograft.315 Alternatively, CEA placed over
deepithelialized allograft (ie, engrafted allodermis) has also proved successful.284
Finally, application of keratinocytes in suspension has shown to improve epider-
mal wound healing in pig316,317 and mouse318,319 models. Reconstitution of the dermal-
epidermal junction was significantly enhanced in an athymic mouse model by suspending
the cells in a fibrin-glue matrix.319 Using a pig model, Currie et al320 recently compared
the effects of keratinocyte cell sprays with and without fibrin glue. No differences in mean
epithelial area or quality of epithelium were noted at 3 weeks. Keratinocyte suspension
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technologyshowspromiseinthatitdoesnotrequirethelengthoftimenecessarytoproduce
cultured epidermal sheets. Use of this technology has proven efficacious in the treatment
of thermal burns in humans.321 A small biopsy is collected and the cells cultured and ex-
panded in a clinical laboratory, then placed into a syringe-like spraying mechanism and
sprayed onto the wound 2 to 5 days following biopsy. This technology is currently available
(CellSpray and CellSpray XP, Clinical Cell Culture, Bentley, Western Australia). These
products are designed for use in partial, deep partial, and full-thickness burns, donor sites,
scar treatment, chronic ulcers, pigment loss, and cosmetic skin rejuvenation following laser
resurfacing, dermabrasion, or chemical peels. A similar spray-on product in development
that delivers allogeneic keratinocytes, fibroblasts, and fibrin to wounds has recently shown
positive results in Phase II trials in Europe and the United States (Allox, IsoTis OrthoBio-
logics, Irvine, Calif). An innovative medical device (ReCell, Clinical Cell Culture, Bentley,
Western Australia) has been developed that will allow rapid harvesting of cells from a thin
split-thickness biopsy followed by spray application onto wounds within 30 minutes of col-
lecting the biopsy, without the need of culturing the keratinocytes in a clinical laboratory.
This single-use device is designed for injuries up to 2% TBSA. It may prove beneficial in
the treatment of small TBSA HD injuries and is worthy of laboratory investigation.
Topical nutritional support
Boyce et al322 noted that application of topical nutrients supports keratinocyte viability
during graft vascularization of cultured skin substitutes and inhibits wound contraction.
There are a large number of “cosmeceutical” products on the market designed to enhance
the appearance, feel, flexibility, and function of skin by supplying moisturizing and nutri-
tive substances. Amino-Plex Spray (biO2 Cosmeceuticals International Inc, Beverly Hills,
Calif)issuchaproductthatisdesignedtoincreaseoxygenincells,stimulateATPsynthesis,
improve glucose transportation, stimulate collagen formation, and promote angiogenesis.
It is a mixture of over 100 low-molecular-weight ingredients, including amino acids, trace
minerals, nucleotides, nucleosides, oligopeptides, electrolytes, glycosaminoglycans, and
glycolipids.Accordingtothecompany,thisproducthasbeenshowntoreduceirritationand
improve results in laser resurfacing, chemical peels, microdermabrasion, hair transplanta-
tion, and hair removal. A new product (Oxy-Mist, biO2 Cosmeceuticals International Inc,
Beverly Hills, Calif) combines the ingredients of Amino-Plex Spray with micellized vita-
min E and sterile mineralized water and uses medical-grade oxygen as the delivery source.
The manufacturer reports that used after facial resurfacing with a pulsed CO2 or erbium
laser, Oxy-Mist has been clinically shown to accelerate reepithelialization, minimize pain,
and decrease the period of postlaser erythema. The oxygen itself likely contributed to the
improved healing noted, as both hyperbaric323 and topical324 oxygen therapies have been
showntofacilitatewoundhealing.Becauseofitsreportedbenefitsindermatologyfollowing
laser resurfacing procedures, it would be advantageous to determine whether these topical
nutritional products will improve the healing of debrided HD injuries.
Vacuum assisted closure
Application of topical negative pressure in the management of chronic wounds and burns
has gained popularity in the last 5 years.325–332 Also known as Vacuum Assisted Closure
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(V .A.C.), the procedure involves placing an open-cell foam into the wound bed (cut to
conform to the shape of the wound), sealing it with an adhesive drape and applying sub-
atmospheric pressure (125 mm Hg below ambient) that is transmitted via an evacuation
tube by a computerized vacuum pump.326,327 The procedure is becoming widely used for
the closure of chronic wounds such as stage III and IV pressure ulcers; venous, arterial,
and neuropathic ulcers; and subacute and acute wounds such as dehisced incisions, split-
thickness meshed skin grafts, and muscle flaps.326,327 V .A.C. is also gaining popularity in
the management of complex orthopedic wounds.329,330 This methodology increases local
blood perfusion and nutrient delivery to the wound, accelerates the rate of granulation tis-
sue formation, and decreases wound tissue bacterial levels.326,327 Per the manufacturer’s
recommendations, wounds must be debrided of all necrotic tissue prior to application of
V .A.C., and it is contraindicated with the presence of nonenteric and unexplored fistulas,
osteomyelitis (untreated), exposed organs or blood vessels, or malignancy in or around the
wound.Thedressingsaretypicallychangedevery1to4daysuntilwoundclosure.V .A.C.has
been shown to be effective in preventing progression of partial-thickness burns to a deeper
injury in a swine model,333 likely the result of helping to deliver oxygen and nutrients to the
zone of stasis. The method has also been shown to increase the rate of skin graft donor site
reepithelialization in pigs and humans331 and is a safe and effective method for securing
split-thickness skin grafts, providing improved graft survival.332 Following debridement of
partial-thickness HD injuries, V .A.C. may prove efficacious in significantly speeding the
reepithelializationprocessintheselesions.Recently,theUSFoodandDrugAdministration
approved the use of V .A.C. in treating partial-thickness burns. The expedited closure of HD
wounds by means of a mechanical force is an area that merits further consideration and
investigation. Several V.A.C. therapy systems are available from Kinetic Concepts Inc, San
Antonio, Tex. One lightweight portable system is available for ambulatory care.
Use of noninvasive bioengineering methods to assess treatment efﬁcacy
Duringefficacytestingofcandidatetreatmentregimens,itisimportanttoexamineanumber
of parameters besides reepithelialization. While coverage of the wound by a new epithe-
lium is important, there are a number of other skin characteristics that are important from a
functional and cosmetic point of view. Surface contour and general appearance, epidermal
hydration, epidermal barrier function, pH, mechanical properties, cutaneous blood flow,
transcutaneous oxygen tension, neural supply/sensory function, and hair growth are all
important characteristics that bear examination. While routine histopathology, immuno-
histochemistry, and electron microscopy are all valued tools in determining morphology
and understanding the pathophysiology of HD wound development and healing, they do
not directly measure physiological parameters or function. For these, a variety of nonin-
vasive bioengineering methods are available. In support of HD wound healing research,
laboratories in the United States and United Kingdom have used reflectance colorime-
try to evaluate erythema, skin hue, chroma, and lightness11,27,83,100,102; LDPI to examine
cutaneous blood flow, depth of injury, neovascularization, and skin graft viability83,101; tor-
sional ballistometry to evaluate the mechanical properties of skin firmness and elasticity83;
evaporimetry to examine transepidermal water loss as a way to evaluate skin hydra-
tion/barrier function83,102; 2-dimensional and 3-dimensional high-frequency (20-MHz) ul-
trasound to examine edema formation11 and scar tissue thickness (J. S. Graham et al,
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unpublished data, 2002); and image analysis to evaluate wound size, shape morphome-
try, and wound contraction.45,100 While not yet used in HD wound healing research ef-
forts, instrumentation is also available for evaluating surface contour, pH, and sensory
function.
SUMMARY
The toxicity of sulfur mustard has been widely described.1,3–16 Cutaneous HD injuries
can take several months to heal, may necessitate lengthy hospitalizations, and can result
in significant cosmetic and/or functional deficits. There are currently no standardized or
optimized methods of casualty management that prevent or minimize deficits and provide
for speedy wound healing.
Research laboratories in the United States, United Kingdom, and Canada have devel-
opedconceptsformedicalcountermeasurestovesicantagents.Theinitialstepinprotecting
a person from the deleterious effects of HD is to eliminate contact with the agent. Protec-
tive gear and topical skin protectants have been designed for this purpose. Should the agent
come in contact with the skin, it needs to be removed within 2 minutes to fully prevent
damage.15 Decontamination is generally performed by physical removal. Sulfur mustard
is not painful on contact and the exposed person may not be aware of the exposure until
symptomsbegintoappearafteralatentperiod.Pharmacologicalapproachesarebeingstud-
ied for their efficacy in minimizing or preventing damage. At this time, it seems clear that
the earliest possible application of anti-inflammatory agents, including cold packs, topi-
cal and systemic steroids, and nonsteroidal anti-inflammatory drugs, is beneficial. Should
HD come in contact with the skin, were decontamination not performed timely, and should
pharmacologicalinterventionbeabsentorineffective,achemicalcasualtywillbeproduced
that requires medical attention. Casualty management now comes into play. There are no
antidotes to HD. Therapy therefore rests on management of symptoms and consequences
of exposure with the intent to reduce long-term morbidity. Historically, blister aspiration
and/or deroofing (epidermal removal), physical debridement, irrigation, topical antibiotics,
and sterile dressings have been the main courses of action in the medical management of
cutaneousHDinjuries.Newstrategiestorelievesymptoms,preventinfections,andpromote
healing have been formulated. Deep cutaneous HD injuries will require aggressive surgical
intervention, including skin grafting, if cosmetic and functional deficits are to be avoided.
Our future research efforts will concentrate on partial-thickness injury that will not require
such aggressive approaches.
Assessment of the injuries must occur early in the process. Total body surface area of
the injuries should be established and depth of injury determined. Laser Doppler perfusion
imaging and ICG fluorescence imaging show promise in prognosticating optimal wound
healing of HD injury on the basis of examination of microcutaneous blood flow. Following
assessment of HD injury, adequate wound debridement needs to be performed. At the
minimum, debridement needs to proceed into normal-appearing skin along the periphery
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The ultimate goal is to determine the most efficacious treatment regimen to be applied
in the clinical management of HD casualties. The ideal regimen should return damaged
skin to optimal appearance and normal function in the shortest time. Improved treatment
will result in a better cosmetic and functional outcome for the patient, and will enable the
casualty to return to normal activities sooner.
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